高カルシウム血症治療市場：薬剤別、重症度別、流通チャネル別、地域別

世界の高カルシウム血症治療市場は、2025年には46億9,000万米ドルと推定され、2032年には83億6,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR8.6％で成長すると予測されます。

図.高カルシウム血症治療市場シェア（%）、2025年地域別

高カルシウム血症は、血液中のカルシウム濃度が異常に高いことを特徴とする病態です。正常なカルシウム調節システムが障害され、副甲状腺が副甲状腺ホルモン（PTH）を過剰産生する場合、または骨吸収が過剰に増加する場合に起こる。高カルシウム血症の一般的な原因には、原発性副甲状腺機能亢進症、ある種のがん、サルコイドーシス、ビタミンDやカルシウムの過剰補給などがあります。高カルシウム血症を放置すると、腎臓、心臓、消化管など複数の臓器に深刻な影響を及ぼす可能性があります。脱水、吐き気、脱力、錯乱、重症の場合は昏睡に至ることもあります。現在の治療には、カルシウムの再吸収と排泄を抑えるビスフォスフォネート、カルシトニン、グルココルチコイドなどの薬剤が用いられています。しかし、安全性と忍容性のプロファイルが改善された新規治療薬には、まだ市場の可能性が残されています。

市場力学：

世界の高カルシウム血症治療市場の成長は、原発性副甲状腺機能亢進症の有病率の上昇、ある種のがん、平均寿命の伸びに牽引されています。また、多発性骨髄腫や乳がん患者ではカルシウム値が高いことが頻繁に観察されます。しかし、ブロックバスター医薬品の特許が切れればジェネリック医薬品が入手可能になるため、市場の成長は抑制される可能性があります。新規のカルシメティックスやカルシウム感受性受容体を標的とした治療薬の開発は、有利な機会を提供します。主要企業による地域展開や地元製薬企業との提携は、革新的な治療オプションの商業化をさらに後押しすると思われます。

本調査の主な特徴

本レポートは、世界の高カルシウム血症治療市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模および複合年間成長率（CAGR%）を提供します。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。

世界の高カルシウム血症治療市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。

本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の高カルシウム血症治療市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。

利害関係者は、世界の高カルシウム血症治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 影響分析
• 主なハイライト
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ
• 疫学

第4章 高カルシウム血症治療市場、薬剤別、2020年-2032年、（10億米ドル）

• ビスフォスフォネート
• カルシウム刺激薬
• カルシトニン
• グルココルチコイド
• デヌソマブ
• カルシトニン
• その他

第5章 高カルシウム血症治療市場、重症度別、2020年-2032年、（10億米ドル）

• 軽度の高カルシウム血症
• 中等度の高カルシウム血症
• 重度の高カルシウム血症

第6章 高カルシウム血症治療市場、流通チャネル別、2020年-2032年、（10億米ドル）

• 病院薬局
• 小売薬局
• オンライン薬局

第7章 世界の高カルシウム血症治療市場、地域別、2020年-2032年、金額（10億米ドル）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第8章 競合情勢

• Pfizer, Inc.
• Ascendis Pharma
• Amgen Inc.
• Cipla
• Hikma Pharmaceuticals, PLC
• Apotex Inc.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals Ltd.
• Sumitomo Pharma Co., Ltd.
• Alkem Labs
• Crinetics Pharmaceuticals, Inc.

第9章 アナリストの推奨事項

• 機会
• アナリストの見解
• Coherent Opportunity Map

第10章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global Hypercalcemia Treatment Market is estimated to be valued at USD 4.69 Bn in 2025 and is expected to reach USD 8.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.

Figure. Hypercalcemia Treatment Market Share (%), By Region 2025

Hypercalcemia is a condition characterized by abnormally high levels of calcium in the blood. It occurs when the normal calcium regulatory system is disrupted and the parathyroid glands overproduce parathyroid hormone (PTH) or when bone resorption increases excessively. Some common causes of hypercalcemia include primary hyperparathyroidism, certain types of cancer, sarcoidosis, and excessive vitamin D or calcium supplementation. If left untreated, hypercalcemia can have severe consequences impacting multiple organs like kidneys, heart, and gastrointestinal tract. It may lead to dehydration, nausea, weakness, confusion, and in severe cases, coma. The current treatment landscape involves medications like bisphosphonates, calcitonin, and glucocorticoids that help reduce calcium resorption and excretion. However, the market still remains open for novel therapies with improved safety and tolerability profiles.

Market Dynamics:

The global hypercalcemia treatment market growth is driven by the rising prevalence of primary hyperparathyroidism, certain types of cancers, and increasing life expectancy. In addition, high calcium levels are frequently observed in patients with multiple myeloma and breast cancer. However, the market growth can be restrained by the availability of generic versions once patents expire on blockbuster drugs. The development of novel calcimimetics and therapies targeting calcium-sensing receptors provide lucrative opportunities. Regional expansions by key players and partnerships with local pharma companies will further aid commercialization of innovative treatment options.

Key Features of the Study:

This report provides in-depth analysis of the global hypercalcemia treatment market and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global hypercalcemia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer, Inc., Ascendis Pharma, Amgen Inc., Cipla, Hikma Pharmaceuticals, PLC, Apotex Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Novartis AG, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Sumitomo Pharma Co., Ltd., Alkem Labs, and Crinetics Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global hypercalcemia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypercalcemia treatment market

Market Segmentation

• By Drug Insights (Revenue, USD Bn, 2019 - 2032)
  • Bisphosphonates
  • Calcimimetic Agents
  • Calcitonin
  • Glucocorticoids
  • Denusomab
  • Calcitonin
  • Others
• By Severity Insights (Revenue, USD Bn, 2019 - 2032)
  • Mild Hypercalcemia
  • Moderate Hypercalcemia
  • Severe Hypercalcemia
• By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Pfizer, Inc.
  • Ascendis Pharma
  • Amgen Inc.
  • Cipla
  • Hikma Pharmaceuticals, PLC
  • Apotex Inc.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Alkem Labs
  • Crinetics Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Hypercalcemia Treatment Market, By Drug
  • Hypercalcemia Treatment Market, By Severity
  • Hypercalcemia Treatment Market, By Distribution Channel
  • Hypercalcemia Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology

4. Hypercalcemia Treatment Market, By Drug, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Bisphosphonates
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Calcimimetic Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Calcitonin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Glucocorticoids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Denusomab
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Calcitonin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Hypercalcemia Treatment Market, By Severity, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Mild Hypercalcemia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Moderate Hypercalcemia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Severe Hypercalcemia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Hypercalcemia Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Hypercalcemia Treatment Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ascendis Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hikma Pharmaceuticals, PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Apotex Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Reddy's Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Glenmark Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sumitomo Pharma Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Alkem Labs
• Crinetics Pharmaceuticals, Inc.

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us